SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the AACR presentations for data on Zymeworks' preclinical or early clinical candidates, which could influence sentiment if results are compelling. No immediate catalyst for valuation change.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.45
T+0 close · Mar 17, 2026 · via day close
Latest settled
−2.07%
T+60 · $22.97
Vs SPY
−13.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $23.45entry
  2. T+1 · 8mo ago +1.90%α +2.16% · $23.90
  3. T+5 · 8mo ago +3.33%α +4.04% · $24.23
  4. T+20 · 7mo ago +15.99%α +9.94% · $27.20
  5. T+60 · 5mo ago −2.07%α −13.59% · $22.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks announced the acceptance of an oral presentation and six abstracts from its R&D portfolio for presentation at the 2026 AACR Annual Meeting. This highlights ongoing research activity but does not represent a material clinical or regulatory milestone.

Key Facts

  • Zymeworks will present one oral presentation and six posters at the AACR Annual Meeting 2026.
  • Presentations are from the company's wholly-owned R&D portfolio.
  • Event takes place April 17–22, 2026, in San Diego, CA.

Financial Impact

No direct financial impact disclosed

Risk Factors

  • Presented data may be preliminary or preclinical, with limited near-term commercial relevance.
  • Lack of detailed results in the press release limits near-term trading catalyst potential.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257732

Track record

25 reports on ZYME

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026